Cardiac & Resuscitation, News

USFA: Ondansetron (Zofran) IV Recall

The Food and Drug Administration (FDA) is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks.

Read More, Ondansetron (Zofran) 32 mg Single Intravenous (IV) Dose Removed due to Potential For Serious Cardiac Risks